China
Africa
Explore chapters and articles related to this topic
Movement disorders
Published in Henry J. Woodford, Essential Geriatrics, 2022
Swallowing disorders (see Chapter 2) are common and can develop even in the early stages of PD.91 These include abnormal tongue control or festination, delayed swallowing reflex and impaired pharyngeal peristalsis. Swallowing problems do not always respond to dopaminergic therapy and can be made worse by intercurrent illness. This may lead to an inability to take usual medications and further functional impairment. This is also an issue when people with PD are made ‘nil by mouth' in the peri-operative period.92 Options include giving medications in a dispersible form via a nasogastric tube, using a transdermal rotigotine patch or a subcutaneous infusion of apomorphine. Equivalent doses of drugs can be calculated – seeTable 9.2. However, initial rotigotine patch doses should not exceed 4 mg/day to reduce the risk of adverse events.
Rotigotine
Published in Anton C. de Groot, Monographs in Contact Allergy, 2021
Rotigotine is a non-ergot dopamine receptor agonist at all five dopamine receptor subtypes (D1-D5) but binds to the D3 receptor with the highest affinity. In addition, it is an antagonist at α2-adrenergic receptors and an agonist at the 5HT1A receptors. Rotigotine, formulated as a once-daily transdermal patch, is indicated for treatment of Parkinson’s disease and moderate-to-severe primary restless legs syndrome. Like other dopamine agonists, rotigotine has been shown to possess antidepressant effects and may be useful in the treatment of depression as well (1).
Degenerative Diseases of the Nervous System
Published in Philip B. Gorelick, Fernando D. Testai, Graeme J. Hankey, Joanna M. Wardlaw, Hankey's Clinical Neurology, 2020
James A. Mastrianni, Elizabeth A. Harris
Rotigotine: Dose 2–8 mg daily.Designed as a daily transdermal patch with slow release.
Pharmacotherapy for post-stroke aphasia: what are the options?
Published in Expert Opinion on Pharmacotherapy, 2023
Marcelo L. Berthier, Guadalupe Dávila
A new option for treating PSA is rotigotine (transdermal patches). Rotigotine is a non-ergoline dopamine agonist that binds all receptors (D1-D5) with a special affinity for D3, and it is approved for treating Parkinson’s disease and restless legs syndrome [82]. Rotigotine is safe in stroke patients and improves post-stroke neglect [82] and language function (spontaneous speech, comprehension, and naming) in a patient with severe mixed transcortical aphasia and linguistic anxiety [83] secondary to two extensive hemorrhages involving left frontal and parietal cortices [84]. Future trials can evaluate the role of rotigotine over more traditional ergoline dopaminergic agents, like bromocriptine, because it has good tolerance and adverse event profile [82]. PWA featuring reduced verbal output and motivation would be the best candidates for dopaminergic stimulation [76,85].
Advancing synthetic therapies for the treatment of restless legs syndrome
Published in Expert Opinion on Pharmacotherapy, 2019
Stefano de Biase, Gaia Pellitteri, Gian Luigi Gigli, Mariarosaria Valente
Rotigotine is usually well tolerated. The most common side effect is represented by application site reactions [56]. Other common side effects are those typical of dopaminergic drugs: nausea, somnolence, dizziness, orthostatic hypotension, headache. Augmentation is reported in patients receiving rotigotine for RLS/WED. It was found to be clinically relevant in 1.5% of 748 patients treated with rotigotine for 6 months in a double-blind, randomized setting (compared with 0.5% of 214 patients on placebo) [57], and in 2.9% of 620 patients treated with rotigotine in a 1-year open-label setting [58]. In a 1-year observational study regarding patients with RLS/WED and augmentation with oral dopamine-agonist treatments, switching from oral therapies to rotigotine was effective in improving RLS/WED symptoms in 37 of the 43 patients (from the original population of 99 patients) who remained in the study over 13 months [57]. Rotigotine has been shown to provide long-term efficacy and safety at a stable dose in a 5-year open-label extension study [56].
Randomized, double-blind, crossover study of the adhesiveness of two formulations of rotigotine transdermal patch in patients with Parkinson’s disease
Published in Current Medical Research and Opinion, 2018
Jan-Peer Elshoff, Lars Bauer, Nadine Goldammer, Marga Oortgiesen, Hanna Pesch, Lars Timmermann
Male or female patients of ≥18 years of age, with a diagnosis of idiopathic PD, were eligible for study participation. Patients were required to have been continuously treated with any dosage of commercially available rotigotine for at least 3 months, and to be on a stable dose of rotigotine including use of an 8 mg/24 hours (40 cm2) patch for at least 2 weeks prior to enrollment. Those who were on a rotigotine dose of >8 mg/24 hours prior to study entry were to take commercial rotigotine patches in addition to the study treatment to achieve their usual rotigotine dose. Patients were to take their usual medications and no concomitant treatments were prohibited; however, patients had to agree to refrain from swimming, bathing or using a sauna during the treatment period.